General Publications December 5, 2016

“A Threat to NJ and Del.’s Primacy as Top Venues for Hatch-Waxman Matters?” New Jersey Law Journal, December 5, 2016.

The Districts of New Jersey and Delaware are recognized as the primary venues for Hatch-Waxman or ANDA (Abbreviated New Drug Application) litigation. But these preferred venues could be in jeopardy in light of the U.S. Supreme Court’s review of the Federal Circuit’s decision in Acorda Therapeutics v. Mylan Pharmaceuticals, writes Maegan Fuller.
Meet the Author
Fuller, Maegan
Senior Associate
Phone: 212.210.9467
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.